EE334 Cost-Effectiveness Analysis of Nivolumab as an Adjuvant Treatment of Muscle-Invasive Urothelial Carcinoma at High Risk of Recurrence in Greece

Dec 1, 2022, 00:00 AM
10.1016/j.jval.2022.09.580
https://www.valueinhealthjournal.com/article/S1098-3015(22)02784-X/fulltext
Section Title :
Section Order : 10115
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02784-X&doi=10.1016/j.jval.2022.09.580
HEOR Topics :
Tags :
Regions :